Incannex Healthcare Limited

Incannex Healthcare Limited engages in the research development and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia It offers APIRx1801 an ultrapure tetrahydrocannabinol APIRx1802 an ultrapure CBD and APIRx1803 an ultrapure cannabigerol The company also develops IHL42X which has completed Phase IIa clinical trial for obstructive sleep apnea PsiGAD that is in Phase IIa clinical trial for generalized anxiety disorder MedChew Dronabinol which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome APIRx1601 which has completed Phase IIa clinical trial for vitiligo APIRx1602 that has completed Phase IIa clinical trial for psoriasis and APIRx1603 which has completed Phase IIa clinical trial for atopic dermatitis In addition its product portfolio includes IHL675A for inflammatory lung disease IHL675A for rheumatoid arthritis IHL675A for inflammatory bowel disease and IHL216A for traumatic brain injuryconcussion which have completed preclinical trials and MedChew 1401 for pain and spasticity in multiple sclerosis MedChew GB for postherpatic neuralgia MedChew1502 for Parkinsons disease MedChew1503 for dementia MedChew RL for restless legs syndrome APIRx 1505 Flotex for chrohns disease CanChew RX and SuppoCan Suppository for inflammatory bowel disease CheWell for addiction of cannabis CanQuit for tobacco smoking cessation CanQuit O for opioid addiction APIRx1701 for glaucoma and APIRx1702 for dry eye syndrome that are in preclinical trials The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020 Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne Australia